Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preclinical Cangrelor in ST-Elevation Myocardial Infarction (Pilot)
2020-005149-18Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Mar 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myocardial infarction (MI) comparing Cangrelor preclinical treatment with Placebo preclinical treatment (2 arms). Primary endpoint: High on-treatment platelet reactivity at emergency department admission. Started Mar 2021; status: completed.
02
Drugs
cangrelor
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2020-005149-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005149-18.